Secondly, the study period ended with 2016, when two major clinical trials [32, 33] changed the perspective on GLP-1 receptor agonists and SGLT-2 inhibitors, which resulted in an updated guidelines on diabetes management in 2018 [4]. Here, GLP1R is linked to diabetes mellitus.